Skip to main content

People in the News: WaferGen Shuffles Board; Spinomix Names Nahas as CEO

Premium

WaferGen Biosystems has shuffled and reduced the size of its board of directors to seven from nine following the firm's acquisition of IntegenX's next-generation sequencing library prep business.

Robert Schueren, IntegenX's CEO, will join WaferGen's board of directors. Prior to his role at IntegenX, Schueren was vice president and general manager of genomics at Agilent Technologies. The board also appointed William McKenzie as a director, effective Dec. 30, 2013. McKenzie most recently served as president and general manager of molecular diagnostics at PerkinElmer.

Scott Davidson and Joseph Pesce, representatives of Great Point Partners, stepped down from the board, as did Robert Coradini and Timothy Triche.


Swiss sample prep company Spinomix said this week that it has appointed Nasri Nahas as CEO.

Nahas was previously CEO of Geneva Bioinformatics, which he joined in 2011. Prior to that, Nahas held various scientific and business positions at biotech companies such as Genset and ValiGen.

Spinomix named Nahas as CEO in conjunction with an announcement that it had reached a milestone in its molecular diagnostics sample prep development plan, triggering an undisclosed second tranche payment from investor Debiopharm.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.